CVS Plans Separation into Two Companies, Raises 2026 EPS Guidance

What happened

CVS Health announced plans to separate into two independent publicly traded companies. Management also raised 2026 adjusted earnings per share guidance to at least $8.20, up from 2025 guidance of $6.30-$6.40. This move represents a significant departure from the integrated payer-PBM-pharmacy model that underpinned the prior BUY thesis in our master report. The separation may address regulatory and investor concerns about conflicts of interest but could sacrifice cross-selling and data synergies. We view the development as a major strategic pivot that requires reassessment of the investment case.

Implication

The separation creates two focused entities that may trade at higher multiples if they are perceived as pure-play businesses. However, the loss of integrated data and care coordination could weaken the combined value proposition for clients. The raised 2026 EPS guidance likely reflects cost savings from separation and possibly improved profitability, but execution risks are substantial. Investors should consider the potential for a sum-of-parts valuation exceeding the current market cap, but also be wary of one-time separation costs and potential customer disruptions. We recommend a cautious approach until more details are provided on the transaction structure and timing.

Thesis delta

The prior BUY stance was based on the integrated platform's moat and restructuring benefits. The planned separation eliminates the integration that was a key source of competitive advantage. However, the raised guidance suggests management expects the separation to unlock value, potentially justifying a higher sum-of-parts valuation. We revise our stance to HOLD pending details on the separation structure and execution plan, as the risk profile has changed materially.